Rethinking Drug Discovery

To kill a cancer cell… or not?

RNA-based drug discovery, new assays? new possibilities?

Beyond PROTACs – what’s next in target protein degradation?

5 key things to look for in a drug discovery CRO partnership

Reducing clinical risk with earlier drug discovery toxicology

The art of selecting the best HTS hits through biophysics

Hit Discovery at Sygnature Discovery

Gender diversity in action at Sygnature

Optimal strategies for hit identification in drug discovery

The benefits of speed and choice; DMPK on its own or in combination with synthesis services

We need new anti-viral medicines more than ever

We’re turning 15!